SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT03857243

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Dual Transcranial Direct Current Stimulation (dTDCS)-Enhanced Therapy After Hemorrhagic Strokes and VEGF

This study will evaluate the feasibility of dual tDCS to improve arm motor function in chronic stroke patients. In addition it will collect pilot data on the blood biomarkers associated with treatment effect.

NCT03857243 Hemorrhagic Stroke Hemiparesis
MeSH:Stroke Paresis Intracranial Hemorrhages
HPO:Cerebral hemorrhage Hemiparesis Intracranial hemorrhage Stroke

1 Interventions

Name: dual transcranial direct current stimulation

Description: Mild, non-invasive battery powered direct current applied to the head over the motor areas. No shaving or invasive procedures needed.
Type: Device
Group Labels: 2

Sham dTDCS plus physical therapy dTDCS plus physical therapy

Primary Outcomes

Description: any adverse events that might be related to study procedures

Measure: Adverse Events

Time: enrollment to 3 month followup

Description: Upper extremity motor impairment scale. Scale ranges from 0 (worst, can not perform any tasks) to 66 ( performs all tasks fully).

Measure: Upper Extremity Fugl-Meyer Score

Time: change between before and 3 months follow-up

Secondary Outcomes

Description: Timed performance of 15 functional upper extremity tasks, 0-120 seconds, and 2 strength measures. WMFT time measurements are calculated as the arithmetic mean of rate of performance, where we calculate "how many times would a person have completed the task, had he or she been performing it continuously for 60 seconds". Therefore the results have a minimum score of 0, where the subject could not perform any of the tasks, and no pre-defined maximum score, the higher the rate score the faster the subject was able to perform the tasks. ( see Hodics et al.,2013)

Measure: Wolf Motor Function Test

Time: change between before and at 3 months follow-up

Purpose: Treatment

Allocation: Randomized

Parallel Assignment

There is one SNP


1 V66M

Since in animal models VEGF and BDNF have a complimentary role, VEGF polymorphism may explain some of the variability in strength of association between BDNF polymorphism Val66Met and recovery. --- Val66Met ---

HPO Nodes